
Residual Solvents: 5 Checks Before You Trust A CoA Line
Residual solvents usually appear on a certificate of analysis as one word: conforms. Here is what the line covers, what it leaves out, and the sentence that turns it into numbers.
Table of Contents
In the pharmaceutical industry, many risks don’t stem from “technological limitations,” but rather from “sudden supply disruptions.”
In recent years, almost all companies, whether innovative drug companies, generic drug companies, or CDMOs, have experienced similar scenarios:
The intermediate quality is fine, and the process is stable, but a critical raw material or a supplier suddenly encounters a problem, forcing the project to halt and delaying the overall timeline.
Based on our long-term experience in intermediate projects, supply chain risk management is no longer just a matter for the procurement department, but a core capability that directly impacts R&D pace, registration compliance, and commercialization progress.
Especially in the intermediate stage, risks are often underestimated, but once they occur, the cost is extremely high.
Many companies have established relatively complete risk management systems at the API level, but are relatively “relaxed” at the intermediate stage. The reasons are quite realistic:
But the reality is quite the opposite.
Intermediates often have the following characteristics:
Once a problem occurs in the intermediate supply chain, even if the API side has production capacity, it cannot proceed.
We have seen this more than once:
Project failure is not due to difficult synthesis, but because of an inconspicuous starting material, for which there are only one or two stable sources globally.
Almost all clients now mention “dual supply,” but truly effective dual supply systems are rare. A common misconception is:
“We already have two suppliers.”
However, in actual audits, many so-called “dual supply” arrangements have significant problems:
A truly valuable dual supply system must meet at least three criteria:
1️⃣ Technically interchangeable
2️⃣ Equivalent quality system
3️⃣ Commercially viable
When assisting clients in establishing a dual supply system, we usually recommend:
At least one project cycle should involve truly utilizing the second supplier to complete a full batch.
In the intermediate supply chain, the real risk points are often concentrated in starting materials and key reagents.
Especially the following types of raw materials:
The risk of these raw materials is not reflected in “whether they can be purchased today,” but rather:
In actual projects, we are more concerned with:
For pharmaceutical companies, instead of repeatedly negotiating lower prices, it is better to establish a more stable technical and planning collaborative relationship with key raw material suppliers.
As regulatory requirements move upstream, more and more clients are realizing that:
The compliance capabilities of intermediate suppliers are themselves a risk variable. Current audit focus has shifted significantly:
In the client audits we participate in, common high-risk issues include:
These issues may not be apparent during normal operations, but they often become magnified risks during registration or on-site inspections.
Therefore, choosing an intermediate partner with a mature compliance system is essentially “buying insurance” for the project in advance.
A realistic but often overlooked fact is:
The flexibility at the API stage often depends on the stability of the intermediate stage.
If the intermediate route, raw materials, and suppliers are sufficiently stable:
This is why more and more companies are choosing to:
Truly mature supply chain risk management is not about fixing problems after they occur, but about clarifying several key questions early in the project:
When these issues are systematically addressed at the intermediate stage, the overall certainty of the project will significantly improve.
In an industry environment where uncertainty is the norm, a stable, auditable, and switchable intermediate supply chain is becoming one of the most realistic competitive advantages for pharmaceutical companies.
Planning your next API or intermediate sourcing decision? →sunqian0123@gmail.com
WhatsApp: +86 176 63713557

Residual solvents usually appear on a certificate of analysis as one word: conforms. Here is what the line covers, what it leaves out, and the sentence that turns it into numbers.

A certificate of analysis does not carry its own expiry date. Batch match, retest window and spec version decide whether it still counts — three dates, five desk checks, five minutes.

A certificate of origin states where the drums were made — and nothing else. Which version your shipment needs, and the checks that keep it from stalling at customs.
Tianming Pharmaceutical is a manufacturer of high-quality pharmaceutical intermediates and fine chemicals for research, development and industrial synthesis. We support global B2B partners with process development, custom synthesis and reliable supply, backed by consistent quality documentation.
Products are supplied as pharmaceutical intermediates for research and industrial use only. They are not for human or veterinary use and are not intended for the manufacture of finished pharmaceutical products without independent regulatory authorization.